Exchange: NASDAQ·Updated 08:33 AM EDT
ALXO logo

ALXOAlx Oncology Holdings Inc

$2.09
$0.04
(1.95%)
Pre-Market
Prev Close $2.05
EarningsAug 11
Mkt Cap$275.85M
Vol152.00
News
all
press releases
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?
bioAffinity's CyPath Lung sales momentum is gaining traction, but wider losses, funding needs and regulatory risks keep pressure on the stock.
Zacks
More News
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
Here is how ALX Oncology Holdings Inc. (ALXO) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Zacks
ALX Oncology (ALXO) to Release Quarterly Earnings on Thursday
ALX Oncology (NASDAQ:ALXO) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-alx-oncology-holdings-inc-stock...
MarketBeat
ALX Oncology (NASDAQ:ALXO) Lowered to "Sell" Rating by Wall Street Zen
Wall Street Zen downgraded ALX Oncology from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?
BIAF is sharpening its focus on CyPath Lung, streamlining unprofitable services and pushing validation studies as it expands its lung-disease pipeline.
Zacks
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update
ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totaling...
MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by Brokerages
ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are currently covering the company, MarketBeat...
MarketBeat
ALX Oncology (NASDAQ:ALXO) CEO Sells $26,714.87 in Stock
ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) CEO Jason Lettmann sold 12,311 shares of the company's stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $2.17, for a total value of $26,714.87. Following the transaction, the chief...
MarketBeat
Insider Selling: ALX Oncology (NASDAQ:ALXO) CEO Sells 12,311 Shares of Stock
ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) CEO Jason Lettmann sold 12,311 shares of the firm's stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an...
MarketBeat
Wells Fargo & Company Begins Coverage on ALX Oncology (NASDAQ:ALXO)
Wells Fargo & Company initiated coverage on ALX Oncology in a research note on Thursday. They issued an "overweight" rating and a $5.00 target price for the company...
MarketBeat
<
1
2
...
>